Previous 10 | Next 10 |
TORONTO, ON / ACCESSWIRE / March 23, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will participate in a Fireside Chat and host one-on-one meetings at the H.C. Wainwright ...
TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AA...
28-day survival will be evaluated in ARDS patients hospitalized with Covid-19 Updated protocol approved by study's ethics committee Company exploring pathways for treating general ARDS patients TORONTO, ON / ACCESSWIRE / March 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinic...
Edesa Biotech press release ( NASDAQ: EDSA ): Q1 GAAP EPS of -$0.13 beats by $0.06 . At December 31, 2022, Edesa had cash and cash equivalents of $8.27 million and working capital of $7.81 million. Subsequent to the end of quarter, the company has received gross proceeds of ap...
TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business. ...
Edesa Biotech ( NASDAQ: EDSA ) said it received approval from Health Canada for a phase 2 trial of EB06 monoclonal antibody to treat vitiligo. Vitiligo is an autoimmune disease that causes skin to lose color in patches. Patients will receive intravenous infusions of either EB...
Company's biologic drug candidate targets a key pathway involved in the progression and maintenance of depigmentation. TORONTO, ON / ACCESSWIRE / February 1, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related disea...
Edesa Biotech ( NASDAQ: EDSA ) stock fell ~33% on Tuesday after the company reported data from a phase 2b trial of skin disorder therapy EB01 The company is exploring EB01 as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) — an itchy ...
Study successfully identified lowest effective dose 1.0% formulation reached primary endpoint with statistical significance Company preparing for End of Phase 2 meeting with FDA following full analysis TORONTO, ON / ACCESSWIRE / January 17, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA)...
Edesa Biotech ( NASDAQ: EDSA ) on Tuesday said it had been granted a fast track designation from the U.S. FDA for its monoclonal antibody candidate EB05 for the treatment of hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS). Shares of the micro-cap clinica...
News, Short Squeeze, Breakout and More Instantly...
Edesa Biotech Inc. Company Name:
EDSA Stock Symbol:
NYSE Market:
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...